News
A Phase 1, First-in-Human Study of CTIM-76, a Claudin-6 (CLDN6)-Directed Bispecific Antibody, in Patients with Recurrent Ovarian Cancer and Other Advanced Solid Tumors
Roisin E. O’Cearbhaill et al.
American Society of Clinical Oncology I Annual Meeting I Abstract TPS2685 I May 30-June 3, 2025
Determination of first in human dose of the T cell-redirecting bispecific antibody CT-95 targeting mesothelin and CD3
Stanley Roberts, Kelly Byrnes-Blake, and Eric Butz
American Association for Cancer Research I Annual Meeting I Abstract 4884 I April 26-30, 2025
Determination of first in human dose of the T cell-redirecting bispecific antibody CTIM-76 targeting Claudin 6
Kelly Byrnes-Blake, Edward Calamai, Stanley Roberts, and Eric Butz
Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting I Abstract 1288 I November 7-11, 2024